Researchers have found that alternol induces ICD in prostate cancer cell lines by increasing DAMPs levels (HMGB1, ATP release, and CRT translocation; pro-inflammatory cytokines such as IL-1 A, IL-1B, IL-8, and IL-6) and stimulating the immune response against tumors in prostate cancer cells. Here, IL6 is linked to prostate cancer.